Gapping up
In reaction to strong earnings/guidance: HOG +6.4%, BMI +5.9%, KSU +5%, EDU +4%, CE +3.9%, TTS +3.8%, GIG+2.7%, UNH +2.2%, SAVE +1.9%, ( raises Q1 operating margin guidance to ~21.5%, up from previous guidance of 19.0 to 20.5% driven by better-than-expected revs), JNJ +1%
M&A news: BUD +2.4% (confirms it has accepted the binding offer from Asahi Group (ASGLY) to acquire certain of SABMiller plc's (SBMRY) European premium brands)
Select EU related names showing strength with DAX up ~2%: STM +3%, UN +2.7%, CS +2.3%, SAP +2.3%, PUK +2%,HSBC +1.8%, DB +1.6%, SAN +1.5%
Select metals/mining stocks trading higher: AG +6.9%, HL +4.5%, CLF +4.3%, BBL +4%, SLW +4%, BHP +4%, SLV+3.9%, AUY +3.6%, GDX +2.3%, NEM +2.2%, MT +1.9%, ABX +1.9%, FCX +1.6%
Other news: HRTX +17.7% (announces that the FDA has indicated that there are no substantive deficiencies in the NDA for SUSTOL), RPRX +14% (continued strenght/momentum), SGYP +9.6% (FDA has determined that its NDA for plecanatide is sufficiently complete to permit a substantive review), PAAS +4.4% (Pan Am Silver and MacMillan Minerals announce arrangement with Maverix Metals to form a new metal royalty and streaming company), CNHI +3.8% (still checking), GFI+3.2% (reports Q1 operational update), MRNS +3.2% (demonstrates 'robust' efficacy in benzodiazepine-resistant model of status epilepticus), RIO +2.1% (reports Q1 production), IMMU +1.7% ( announces labetuzumab govitecan continues to produce 'encouraging' survival results in a multicenter, open-label Phase 2 study ), DEO +1.7% (in sympathy with Remy Cointrea (better than expected earnings in EU)), WHR +1.6% (authorizes $1 bln share repurchase program; raises quarterly dividend by 11% to $0.90 per share), DVAX +1.4% (presents encouraging data from clinical trial of immuno-oncology product candidate SD-101 and preesents Pivotal Phase 3 data showing HEPLISAV-B provided significantly higher protection against Hepatitis B than Engerix-B ), HALO +1.3% (announces pre-clinical data for the discovery & early development of 2 potential drug candidates ), ARIA +0.9% (presents preclinical data supporting upcoming clinical testing in Non-Small Cell Lung Cancer patients with EGFR and HER2 Exon 20 mutations)
Analyst comments: DVN +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), ESV +1.4% (upgraded to Hold from Sell at DNB Markets)
In reaction to strong earnings/guidance: HOG +6.4%, BMI +5.9%, KSU +5%, EDU +4%, CE +3.9%, TTS +3.8%, GIG+2.7%, UNH +2.2%, SAVE +1.9%, ( raises Q1 operating margin guidance to ~21.5%, up from previous guidance of 19.0 to 20.5% driven by better-than-expected revs), JNJ +1%
M&A news: BUD +2.4% (confirms it has accepted the binding offer from Asahi Group (ASGLY) to acquire certain of SABMiller plc's (SBMRY) European premium brands)
Select EU related names showing strength with DAX up ~2%: STM +3%, UN +2.7%, CS +2.3%, SAP +2.3%, PUK +2%,HSBC +1.8%, DB +1.6%, SAN +1.5%
Select metals/mining stocks trading higher: AG +6.9%, HL +4.5%, CLF +4.3%, BBL +4%, SLW +4%, BHP +4%, SLV+3.9%, AUY +3.6%, GDX +2.3%, NEM +2.2%, MT +1.9%, ABX +1.9%, FCX +1.6%
Other news: HRTX +17.7% (announces that the FDA has indicated that there are no substantive deficiencies in the NDA for SUSTOL), RPRX +14% (continued strenght/momentum), SGYP +9.6% (FDA has determined that its NDA for plecanatide is sufficiently complete to permit a substantive review), PAAS +4.4% (Pan Am Silver and MacMillan Minerals announce arrangement with Maverix Metals to form a new metal royalty and streaming company), CNHI +3.8% (still checking), GFI+3.2% (reports Q1 operational update), MRNS +3.2% (demonstrates 'robust' efficacy in benzodiazepine-resistant model of status epilepticus), RIO +2.1% (reports Q1 production), IMMU +1.7% ( announces labetuzumab govitecan continues to produce 'encouraging' survival results in a multicenter, open-label Phase 2 study ), DEO +1.7% (in sympathy with Remy Cointrea (better than expected earnings in EU)), WHR +1.6% (authorizes $1 bln share repurchase program; raises quarterly dividend by 11% to $0.90 per share), DVAX +1.4% (presents encouraging data from clinical trial of immuno-oncology product candidate SD-101 and preesents Pivotal Phase 3 data showing HEPLISAV-B provided significantly higher protection against Hepatitis B than Engerix-B ), HALO +1.3% (announces pre-clinical data for the discovery & early development of 2 potential drug candidates ), ARIA +0.9% (presents preclinical data supporting upcoming clinical testing in Non-Small Cell Lung Cancer patients with EGFR and HER2 Exon 20 mutations)
Analyst comments: DVN +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), ESV +1.4% (upgraded to Hold from Sell at DNB Markets)